<DOC>
	<DOCNO>NCT00223990</DOCNO>
	<brief_summary>This trial currently evaluate one candidate malaria vaccine , FMP1/AS02A . This candidate malaria vaccine develop routine immunization infant child live malaria-endemic area . This vaccine would offer protection malaria disease due parasite Plasmodium falciparum . Prior start study , FMP1/AS02A give approximately 60 malaria-na√Øve adult 40 adult 90 child live malaria-endemic region . This study investigate whether candidate vaccine prevent malaria disease 6 month post-vaccination . One half enrolled subject receive FMP1/AS02A half rabies vaccine .</brief_summary>
	<brief_title>Double-blind , Randomized , Controlled Study Safety , Immunogenicity Efficacy Candidate Malaria Vaccine</brief_title>
	<detailed_description>Full , Unabbreviated Title : A Double-blind , Randomized , Controlled , Phase IIb Field Trial 12 47 Month-old Children Western Kenya Evaluate Efficacy , Safety Immunogenicity FMP1/AS02A Malaria Vaccine ( WRAIR 's MSP-1 Antigen Adjuvanted GlaxoSmithKline 's AS02A ) Versus Rabies Vaccine</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : A healthy male female child , 12 47 month age day screen Written informed consent obtain least one parent/guardian study start Available participate study duration ( 14 month ) Acute disease time entry study opinion investigator may pose threat subject Prior receipt rabies vaccine investigational vaccine Use investigational drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use 30 day third dose Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within six month vaccination . ( For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day . Inhaled topical steroid allow ) Administration anticipate administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) exception tetanus toxoid Previous vaccination vaccine contain MPL QS21 ( e.g. , RTS , S/AS02A ) Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . ( No HIV test perform part study . ) History allergic reaction anaphylaxis immunization vaccine component , eggs History surgical splenectomy Administration immunoglobulins , blood transfusion , blood product within six month precede first dose study vaccine plan administration study period Simultaneous participation clinical trial Acute chronic cardiovascular , pulmonary , hepatic , renal condition opinion PI , may increase risk subject participate study Any condition circumstance opinion investigator may pose threat subject</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Plasmodium</keyword>
	<keyword>falciparum</keyword>
	<keyword>malaria</keyword>
	<keyword>vaccine</keyword>
	<keyword>AS02A adjuvant</keyword>
	<keyword>FMP1</keyword>
	<keyword>Merozoite surface protein-1</keyword>
</DOC>